Open-label placebos as adjunctive therapy for patients with depression

Area of Science:

• Psychiatry
• Clinical Psychology
• Medical Ethics

Background:

• Prescribing placebos as regular medication can alleviate depression symptoms.
• Administering placebos without informed consent raises ethical concerns.
• Open-label placebos (OLPs) offer a potential ethical alternative for placebo interventions.

Purpose of the Study:

• To assess the efficacy of open-label placebos (OLPs) when used concurrently with cognitive-behavioral therapy (CBT).
• To evaluate the impact of OLP on depression symptom reduction and patient adherence.
• To explore the ethical implications and patient acceptance of OLPs in depression treatment.

Main Methods:

• Sixty patients with major depressive disorder were enrolled.
• Participants were randomly assigned to a 4-week CBT program with or without daily OLP.
• Assessments were conducted pre-program, post-program, and at three-month follow-up.

Main Results:

• The CBT + OLP group exhibited a greater reduction in depression symptoms post-treatment compared to the CBT-only group.
• No significant differences in depression severity changes were observed between the groups.
• Noncompliance with follow-up appointments was significantly higher in the CBT + OLP group (27%) versus the CBT group (7%), associated with negative OLP evaluations.

Conclusions:

• While OLPs reduced depression symptoms, the changes were not clinically significant.
• OLP use was associated with an increased risk of patient dropout.
• The high dropout rate suggests potential challenges in the acceptance and integration of OLPs for depression treatment.